Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia

Journal of Virology

Volumn 89, Issue 2, 2015, Pages 962-969

  Meysman, Pieter ^a   Ogunjimi, Benson ^a,b   Naulaerts, Stefan ^a   Beutels, Philippe ^a   Van Tendeloo, Viggo ^a   Laukensa, Kris ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA A2 ANTIGEN; HLA A33 ANTIGEN; HLA B ANTIGEN; HLA B40 ANTIGEN; HLA B44 ANTIGEN; HLA DRB1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; GENOTYPE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; META ANALYSIS (TOPIC); POSTHERPETIC NEURALGIA; PROTEIN BINDING; RISK FACTOR; VARICELLA ZOSTER VIRUS; VIRUS GENOME; DISEASE PREDISPOSITION; GENE FREQUENCY; GENETICS; IMMUNOLOGY; META ANALYSIS; NEURALGIA, POSTHERPETIC;

HUMAN HERPESVIRUS 3;

DISEASE SUSCEPTIBILITY; GENE FREQUENCY; GENOTYPE; HERPESVIRUS 3, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; NEURALGIA, POSTHERPETIC; RISK FACTORS;

EID: 84920825213     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02500-14     Document Type: Article

References (47)

1. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. 2010. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 48(Suppl 1):S2-S7. http://dx.doi.org/10.1016/S1386-6532(10)70002-0.
2. Hope-Simpson RE. 1965. The nature of herpes zoster: a long-term study and a new hypothesis. J R Soc Med 58:9-20.
3. Viner K, Perella D, Lopez A, Bialek S, Newbern C, Pierre R, Spells N, Watson B. 2012. Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings. J Infect Dis 205:1336-1341. http://dx.doi.org/10.1093/infdis/jis207.
4. Thomas SL, Hall AJ. 2004. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 4:26-33. http://dx.doi.org/10.1016/S1473-3099(03)00857-0.
5. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. 2010. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 8:37. http://dx.doi.org/10.1186/1741-7015-8-37.
6. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. 2010. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J 182:1731-1736. http://dx.doi.org/10.1503/cmaj.091711.
7. Ultsch B, Köster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O. 2013. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 14:1015-1026. http://dx.doi.org/10.1007/s10198-012-0452-1.
8. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan ISF, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ. 2009. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 200:1068-1077. http://dx.doi.org/10.1086/605611.
9. Barton JC, Barton JC, Bertoli LF. 2012. Predictors of shingles reports at diagnosis of common variable immunodeficiency and selective immunoglobulinGsubclass deficiency in 212 Alabama adults. Infect Dis Rep 4:e34. http://dx.doi.org/10.4081/idr.2012.e34.
10. Opstelten W, Zuithoff NPA, Van Essen GA, Van Loon AM Van Wijck AJM, Kalkman CJ, Verheij TJM, Moons KGM. 2007. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 132(Suppl 1):S52-S59. http://dx.doi.org/10.1016/j.pain.2007.02.004.
11. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Annunziato PW, Silber JL. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271-2284. http://dx.doi.org/10.1056/NEJMoa051016.
12. Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. 2008. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol 144:603-608. http://dx.doi.org/10.1001/archderm.144.5.603.
13. Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. 1995. Racial differences in the occurrence of herpes zoster. J Infect Dis 171:701-704. http://dx.doi.org/10.1093/infdis/171.3.701.
14. Schmader K, George LK, Burchett BM, Pieper CF. 1998. Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis 178: S67-S70. http://dx.doi.org/10.1086/514254.
15. Ozawa A, Sasao Y, Iwashita K, Miyahara M, Sugai J, Iizuka M, Kawakubo Y, Ohkido M, Naruse T, Anzai T, Takashige N, Ando A, Inoko H. 1999. HLA-A33 and-B44 and susceptibility to postherpetic neuralgia (PHN). Tissue Antigens 53:263-268. http://dx.doi.org/10.1034/j.1399-0039.1999.530306.x.
16. Sato M, Ohashi J, Tsuchiya N, Kashiwase K, Ishikawa Y, Arita H, Hanaoka K, Tokunaga K, Yabe T. 2002. Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population. Genes Immun 3:477-481. http://dx.doi.org/10.1038/sj.gene.6363890.
17. Sato-Takeda M, Ihn H, Ohashi J, Tsuchiya N, Satake M, Arita H, Tamaki K, Hanaoka K, Tokunaga K, Yabe T. 2004. The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster. Pain 110:329-336. http://dx.doi.org/10.1016/j.pain.2004.04.010.
18. Sumiyama D, Kikkawa EF, Kita YF, Shinagawa H, Mabuchi T, Ozawa A, Inoko H. 2008. HLA alleles are associated with postherpetic neuralgia but not with herpes zoster. Tokai J Exp Clin Med 33:150-153.
19. Yewdell JW. 2006. Confronting complexity: real-world immunodomi-nance in antiviral CD8+ T cell responses. Immunity 25:533-543. http://dx.doi.org/10.1016/j.immuni.2006.09.005.
20. Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V. 2008. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 9:8. http://dx.doi.org/10.1186/1471-2172-9-8.
21. Lundegaard C, Lund O, Nielsen M. 2012. Predictions versus highthroughput experiments in T-cell epitope discovery: competition or synergy? Expert Rev Vaccines 11:43-54. http://dx.doi.org/10.1586/erv.11.160.
22. Zhang L, Udaka K, Mamitsuka H, Zhu S. 2012. Toward more accurate pan-specific MHC-peptide binding prediction: a review of current methods and tools. Brief Bioinform 13:350-364. http://dx.doi.org/10.1093/bib/bbr060.
23. Larsen ME, Kornblit B, Larsen MV, Masmas TN, Nielsen M, Thiim M, Garred P, Stryhn A, Lund O, Buus S, Vindelov L. 2010. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 16:1370-1381. http://dx.doi.org/10.1016/j.bbmt.2010.03.022.
24. Hertz T, Oshansky C, Roddam P, DeVincenzo J, Caniza M, Jojic N, Mallal S, Phillips E, James I, Halloran M, Thomas P. 2013. HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. Proc Natl Acad Sci USA 110: 13492-13497. http://dx.doi.org/10.1073/pnas.1221555110.
25. Stranzl T, Larsen MV, Lundegaard C, Nielsen M. 2010. NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics 62:357-368. http://dx.doi.org/10.1007/s00251-010-0441-4.
26. Peters B, Sette A. 2005. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6:132. http://dx.doi.org/10.1186/1471-2105-6-132.
27. Dang TH, Van Leemput K, Verschoren A, Laukens K. 2008. Prediction of kinase-specific phosphorylation sites using conditional random fields. Bioinformatics 24:2857-2864. http://dx.doi.org/10.1093/bioinformatics/btn546.
28. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, Damle R, Sette A, Peters B. 2010. The immune epitope database 2.0. Nucleic Acids Res 38:D854-D862. http://dx.doi.org/10.1093/nar/gkp1004.
29. Lafferty J, McCallum A, Pereira F. 2001. Conditional random fields: probabilistic models for segmenting and labeling sequence data. Proceedings of the 18th International Conference on Machine Learning. San Francisco, CA, p 282-289.
30. Meysman P, Dang TH, Laukens K, De Smet R, Wu Y, Marchal K, Engelen K. 2011. Use of structural DNA properties for the prediction of transcription-factor binding sites in Escherichia coli. Nucleic Acids Res 39:e6. http://dx.doi.org/10.1093/nar/gkq1071.
31. Wang M, Weiss M, Simonovic M, Haertinger G, Schrimpf SP, Hengartner MO, von Mering C. 2012. PaxDb, a database of protein abundance averages across all three domains of life. Mol Cell Proteomics 11: 492-500. http://dx.doi.org/10.1074/mcp.O111.014704.
32. Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. 2013. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol 191:5831-5839. http://dx.doi.org/10.4049/jimmunol.1302101.
33. Chiu C, McCausland M, Sidney J, Duh F-M, Rouphael N, Mehta A, Mulligan M, Carrington M, Wieland A, Sullivan NL, Weinberg A, Levin MJ, Pulendran B, Peters B, Sette A, Ahmed R. 2014. Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV. PLoS Pathog 10:e1004008. http://dx.doi.org/10.1371/journal.ppat.1004008.
34. Forghani B, Mahalingam R, Vafai A, Hurst JW, Dupuis KW. 1990. Monoclonal antibody to immediate early protein encoded by varicellazoster virus gene 62. Virus Res 16:195-210. http://dx.doi.org/10.1016/0168-1702(90)90023-5.
35. Zerboni L, Sobel R. 2010. Expression of varicella-zoster virus immediateearly regulatory protein IE63 in neurons of latently infected human sensory ganglia. J Virol 84:3421-3430. http://dx.doi.org/10.1128/JVI.02416-09.
36. Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, Guruge D, Ogg GS. 2010. IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. Br J Cancer 102:727-730. http://dx.doi.org/10.1038/sj.bjc.6605542.
37. Schmader K. 1998. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 16:1768-1770. http://dx.doi.org/10.1016/S0264-410X(98)00137-6.
38. Kawai K, Gebremeskel BG, Acosta CJ. 2014. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 4:e004833. http://dx.doi.org/10.1136/bmjopen-2014-004833.
39. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernández-Viña MA. 2001. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62:1009-1030. http://dx.doi.org/10.1016/S0198-8859(01)00298-1.
40. Saethang T, Hirose O, Kimkong I, Tran VA, Dang XT, Nguyen LAT, Le TKT, Kubo M, Yamada Y, Satou K. 2013. PAAQD: predicting immunogenicity of MHC class I binding peptides using amino acid pairwise contact potentials and quantum topological molecular similarity descriptors. J Immunol Methods 387:293-302. http://dx.doi.org/10.1016/j.jim.2012.09.016.
41. Kennedy PGE, Cohrs RJ. 2010. Varicella-zoster virus human ganglionic latency: a current summary. J Neurovirol 16:411-418. http://dx.doi.org/10.1007/BF03210846.
42. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439-1443. http://dx.doi.org/10.1126/science.1069660.
43. Westover KM, Hughes AL. 2007. Evolution of cytotoxic T-lymphocyte epitopes in hepatitis B virus. Infect Genet Evol 7:254-262. http://dx.doi.org/10.1016/j.meegid.2006.10.004.
44. Irausquin SJ, Hughes AL. 2010. Conflicting selection pressures target the NS3 protein in hepatitis C virus genotypes 1a and 1b. Virus Res 147:202-207. http://dx.doi.org/10.1016/j.virusres.2009.11.001.
45. Abendroth A, Kinchington PR, Slobedman B. 2010. Varicella zoster virus immune evasion strategies. Curr Top Microbiol Immunol 342:155-171. http://dx.doi.org/10.1007/82_2010_41.
46. Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, Arvin AM. 2003. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 188:40-52. http://dx.doi.org/10.1086/375828.
47. Ogunjimi B, Smits E, Heynderickx S, Van den Bergh J, Bilcke J, Jansens H, Malfait R, Ramet J, Maecker HT, Cools N, Beutels P, Van Damme P. 2014. Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians. Clin Vaccine Immunol 21:417-426. http://dx.doi.org/10.1128/CVI.00818-13.